Every recall we track for Cipla USA, Inc. — 23 in all — plus the complaints and injury reports the public filed about them.
Cipla USA recalls 60mg Cinacalcet tablets due to potential N-nitroso-cinacalcet above safe levels. Affected lots from 2023-2027; stop using if you have these specific batches.
Cipla USA recalls 90mg Cinacalcet tablets due to potential N-nitroso-cinacalcet levels exceeding safe limits. This prescription drug may pose health risks if taken as directed.
Cipla USA recalls 30mg Cinacalcet tablets with N-nitroso-cinacalcet above safe daily intake levels. Consumers should contact Cipla for details on affected lots and return instructions.
Cipla USA recalls 60mg Cinacalcet tablets due to N-Nitroso contamination exceeding safe limits. Affected lots manufactured in India with specific expiry dates. Consumers should contact Cipla for details.
Cipla USA recalls 90mg Cinacalcet tablets due to N-Nitroso contamination exceeding safe limits. Rx-only medication with specific lot numbers and expiration dates. Consumers should contact Cipla for details.
Cipla USA recalls 30mg Cinacalcet tablets due to N-Nitroso contamination exceeding safe limits. Affected lots manufactured in India for US distribution. Consumers should contact Cipla for details.
Cipla USA recalls Lanreotide injection due to potential lack of sterility in manufacturing. Products with specific NDC numbers and expiration dates are affected. Consumers should check their product details and contact Cipla for guidance.
Cipla USA recalls Lanreotide Injection 120 mg/0.5 mL syringes due to potential contamination from inadequate visual inspection at manufacturing. This could lead to infections if used.
Cipla USA recalls 200mg Nilotinib capsules due to stability concerns at 6 months. Affected lots may show appearance issues. Contact for return instructions.
Cipla USA recalls 150mg Nilotinib capsules with stability concerns. Products may show appearance issues after 6 months. Check NDC 69097-031-74 for affected lots.
Cipla USA recalls Lanreotide Injection 120 mg/0.5 mL syringes due to particulate matter. Affected lots expire through 2027. Stop using if you have these specific lot numbers.
Cipla USA recalls 1% Diclofenac Sodium Topical Gel due to failed pharmaceutical specifications. Consumers should check NDC 76282-103-39 and batch XHBG for affected units.
Cipla USA recalls 60mg Cinacalcet tablets due to nitrosamine impurity exceeding safe limits. Patients should consult their doctor before using affected products.
Cipla USA recalls 30mg Cinacalcet tablets due to nitrosamine impurity exceeding safe limits. Patients with high calcium levels should stop using these specific lots.
Cipla USA recalls 90mg Cinacalcet tablets due to nitrosamine impurity exceeding safe limits. Patients should consult their doctor for alternatives.
Cipla USA recalls Lanthanum Carbonate chewable tablets due to hardness test failure. Affected products have specific NDC numbers and lot numbers. Consumers should contact the manufacturer for details.
Cipla USA recalls 1000mg Lanthanum Carbonate chewable tablets due to hardness test failure. This may affect tablet integrity and safety. Check your Rx-only medication packaging for the recall.
Cipla USA recalls albuterol inhalers with potential particle size issues. This may affect stability and safety. Check your NDC 69097-142-60 lot 4IB0519 for affected units.
Cipla USA recalls 0.5mg/2ml Budesonide inhaler ampules due to leakage and empty ampoules. Stop using if you have the specific batch.
Cipla recalls 0.5 mg & 3mg/3mL inhalation solution vials due to reported short fill volume and few drops in pouches. Affected units may have less medication than labeled.
